stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
128.00
8.87
+7.45%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Net margin
GRAIL, Inc.'s net margin over the twelve months to 30 September 2026 was −243.8%, up 33.7 percentage points from fiscal 2025 (−277.5%). That is below the Diagnostics & Research industry median of −4.10% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −277.5% | 1,336.45 |
| FY2024 | −1,613.9% | (39.69) |
| FY2023 | −1,574.2% | 8,145.12 |
| FY2022 | −9,719.4% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | −275.9% | (29.21) |
| Jun 2026 | −246.7% | (18.23) |
| Mar 2026 | −228.5% | (1.00) |
| Dec 2025 | −227.5% | 18.35 |
| 9 more quarters | Free account |
Net margin against peers
| Company | Net margin |
|---|---|
| CDNA CareDx, Inc. compare | 25.9% |
| VCYT Veracyte, Inc. compare | 21.8% |
| QGEN QIAGEN N.V. compare | 19.5% |
| SHC Sotera Health Company compare | 14.1% |
| BLLN BillionToOne, Inc. compare | 11.2% |
| ICLR ICON PLC compare | 5.45% |
| RDNT RadNet, Inc. compare | −0.93% |
| ADPT Adaptive Biotechnologies Corporation compare | −23.7% |
| GRAL GRAIL, Inc. | −243.8% |
| Diagnostics & Research industry median | −4.10% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement